Molecular Chaperones in Neurodegeneration

Introduction

Molecular Chaperones In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Molecular chaperones — particularly heat shock proteins (HSPs) — are essential components of the cellular protein quality control system that prevents the accumulation of misfolded and aggregated proteins characteristic of neurodegenerative diseases^{1'Wyttenbach A, The role of heat shock proteins during neurodegeneration in Alzheimer''s, Parkinson''s and Huntington''s Disease. In: *Bentham Science eBook*, 2007'2007Open reference}. The hallmark pathology of Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, and ALS involves the deposition of specific misfolded proteins — amyloid-beta and tau, alpha-synuclein, huntingtin, and TDP-43/SOD1, respectively — suggesting that failure of the chaperone network is a central contributor to disease progression^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}.

Major Chaperone Families

HSP70 (HSPA) Family

The HSP70 family, including the constitutively expressed Hsc70 (HSPA8) and the stress-inducible Hsp70 (HSPA1A), represents the most versatile and^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference} extensively studied chaperone system in neurodegeneration^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}. HSP70 functions through an ATP-dependent cycle of substrate binding and release,^{5Small heat shock proteins in neurodegenerative diseases. *Cell Stress Chaperones*. 2024;29(2):338-3552024 · DOI 10.1016/j.cstres.2023.12.001Open reference} guided by co-chaperones that determine substrate specificity and fate^{6Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease. *Nat Genet*. 2009;41(10):1088-10932009 · DOI 10.1038/ng.440Open reference}:

• J-domain proteins (JDPs/Hsp40): DNAJB1 and other J-domain proteins serve as specificity factors that recognize misfolded substrates and deliver them to HSP70. DNAJB1 specifically recognizes the oligomeric form of alpha-synuclein through multivalent interactions and targets HSP70 to amyloid fibril surfaces^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}.

• Nucleotide exchange factors (NEFs): HSP110 (HSPH1) and BAG family proteins accelerate ADP release from HSP70, facilitating substrate release. HSP110 is critical for the disaggregation activity of the HSP70 machinery^{7" Molecular dissection of amyloid disaggregation by human HSP70. *Nature*. 2020;587:483-488"2020 · DOI 10.1038/s41586-020-2904-6Open reference}.

The HSP70 disaggregation machinery (Hsc70-DNAJB1-Apg2/HSP110) can completely reverse alpha-synuclein amyloid fibrils back to the soluble monomeric^{8" Hsp70 inhibits the nucleation and elongation of tau and sequesters tau aggregates with high affinity. *ACS Chem Biol*. 2018;13(3):560-571"2018 · DOI 10.1021/acschembio.7b01039Open reference} state through a mechanism where monomer units are removed directly from fibril ends via first-order kinetics^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}0. This^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}1 remarkable activity demonstrates that amyloid fibrils are not irreversible endpoints but can be disassembled by the endogenous chaperone machinery^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}2 ^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}3^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}4.

HSP90 (HSPC) Family

Hsp90 plays a complex and sometimes paradoxical role in neurodegeneration. Unlike HSP70, which primarily promotes clearance of misfolded proteins,^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}5 HSP90 can stabilize and maintain client proteins in a folding-competent state — including disease-associated proteins like tau and mutanthuntingtin^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}6.

• HSP90 and tau: HSP90 stabilizes abnormally phosphorylated tau, preventing its degradation. Pharmacological inhibition of HSP90 promotes tau clearance via the ubiquitin-proteasome-system and autophagy^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}7.

• HSP90 inhibitors: Drugs that inhibit HSP90 (e.g., geldanamycin derivatives, ganetespib) induce a compensatory heat shock response that upregulates HSP70 and other protective chaperones, providing dual therapeutic benefit — destabilizing toxic client proteins while boosting the protective chaperone network^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}8.

Small Heat Shock Proteins (sHSPs)

Small HSPs (HSPB1/Hsp27, HSPB5/αB-crystallin, HSPB8) are ATP-independent chaperones that function as “holdases,” binding to partially unfolded proteins and preventing their aggregation until they can be refolded by the HSP70/HSP90 machinery or targeted for degradation^{2" The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. *Front Neurosci*. 2017;11:254"2017 · DOI 10.3389/fnins.2017.00254Open reference}9.

• HSPB1 (Hsp27): Overexpression reduces tau hyperphosphorylation and amyloid-beta toxicity in Alzheimer’s Disease models. Mutations in HSPB1 cause Charcot-Marie-Tooth Disease type 2F and distal hereditary motor neuropathy.

• HSPB5 (αB-crystallin): Found in Lewy bodies in Parkinson’s Disease and in senile plaques in Alzheimer’s Disease, suggesting it co-localizes with aggregating proteins in an attempt to prevent or mitigate aggregation.

• HSPB8: Particularly relevant to ALS and motor neuron diseases. Mutations in HSPB8 cause distal motor neuropathy. HSPB8, in complex with BAG3, mediates selective autophagy of aggregation-prone proteins including mutant SOD1 and TDP-43^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}0.

HSP60 (HSPD) Family

HSP60, primarily localized in mitochondria, assists in the folding of imported mitochondrial proteins. Reduced HSP60 levels have been observed inAlzheimer’s Disease and Parkinson’s Disease brains, and loss of HSP60 function contributes to mitochondrial-dysfunction^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}1. Mutations in HSPD1 cause hereditary spastic paraplegia type 13 (SPG13), directly linking mitochondrial chaperone dysfunction to neurodegeneration^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}2.

Chaperone Interactions with Disease Proteins

Amyloid-Beta (Aβ) — Alzheimer’s Disease

HSP70 interacts with amyloid-beta at multiple stages of the aggregation pathway. It can bind amyloid-beta monomers to prevent oligomer formation, sequester toxic oligomers, and disassemble preformed fibrils^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}3. The extracellular chaperone clusterin (CLU/ApoJ) also plays a crucial role in clearing amyloid-beta from the brain, and the CLU gene is a major genetic risk factor for late-onsetAlzheimer’s Disease^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}4.

Tau — Tauopathies

The HSP70/HSP90 chaperone system is a central regulator of tau homeostasis. HSP70 inhibits the early stages of tau-protein aggregation by suppressing the formation of tau nuclei, and sequesters tau oligomers and mature fibrils with nanomolar affinity into a protective complex that efficiently neutralizes their ability to damage membranes and seed further aggregation^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}5. The co-chaperone CHIP (C-terminus of Hsc70-interacting protein) ubiquitinates tau for proteasomal degradation, and reduced CHIP levels correlate with tau accumulation in Alzheimer’s Disease^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}6.

Alpha-Synuclein — Synucleinopathies

alpha-synuclein aggregation in Parkinson’s Disease, Lewy Body Dementia, and MSA is counteracted by the HSP70 disaggregation machinery. The trimeric complex of Hsc70, DNAJB1, and Apg2 removes alpha-synuclein monomers directly from fibril ends^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}7. HSP90 modulates the assembly of alpha-synuclein into vesicle-associated forms, and its inhibition can paradoxically increase alpha if compensatory HSP70 upregulation is insufficient^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}8.

TDP-43 and SOD1 — ALS/FTD

TDP-43 mislocalization and aggregation in ALS and FTD are modulated by HSP70 and small HSPs. HSPB8-BAG3 complex targets TDP-43 aggregates for autophagic clearance. For mutant SOD1, HSP70 can stabilize the native conformation and prevent misfolding, while HSP90 inhibition promotes clearance of misfolded SOD1 species^{3" The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends. *Nat Commun*. 2021;12:5999"2021 · DOI 10.1038/s41467-021-25966-wOpen reference}9.

Huntingtin — Huntington’s Disease

Expanded polyglutamine repeats in huntingtin overwhelm the chaperone system, and HSP70 and HSP40 co-localize with huntingtin aggregates in inclusion bodies^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}0. Overexpression of HSP70 and HSP40 suppresses polyglutamine-aggregation and toxicity in cell and animal models. DNAJB6 is particularly effective at suppressing polyglutamine aggregation^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}1.

Aging and Chaperone Decline

The proteostasis network undergoes significant decline during aging, which is the primary risk factor for most neurodegenerative diseases^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}2. Key age-related changes include:

• Reduced heat shock response: The transcription factor HSF1 (Heat Shock Factor 1), which drives expression of inducible HSPs, shows decreased activity with age. HSF1 activation is impaired in aged neurons, reducing their capacity to upregulate protective chaperones in response to stress.

• Decreased chaperone levels: Brain concentrations of HSP70, HSP90, and small HSPs decline with age, correlating with increased vulnerability to protein aggregation.

• Impaired co-chaperone function: Age-related changes in co-chaperone expression and activity alter substrate triage decisions, potentially shifting the balance from refolding toward aggregation.

• Overwhelmed capacity: As age-related protein damage accumulates, the remaining chaperone capacity becomes increasingly insufficient to maintain proteostasis, creating a vicious cycle of aggregation and chaperone sequestration.

Therapeutic Strategies

HSP90 Inhibitors

Pharmacological inhibition of HSP90 triggers a compensatory heat shock response through HSF1 activation, upregulating HSP70 and other protective chaperones. Several HSP90 inhibitors have shown efficacy in neurodegenerative disease models^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}3:

• 17-AAG (tanespimycin): Reduced tau pathology in Alzheimer’s Disease models

• Ganetespib: Promoted clearance of mutant SOD1 in ALS models

• SNX-2112: Reduced alpha-synuclein toxicity in Parkinson’s Disease models

Direct HSP70 Modulators

• Arimoclomol: A co-inducer of the heat shock response that amplifies HSP70 expression. Advanced to Phase III clinical trials for ALS but failed to show significant benefit, highlighting the challenge of translating chaperone-based therapies to clinical practice^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}4.

• YM-1 and JG-98: Allosteric modulators of HSP70 that alter its substrate triage decisions, directing tau toward degradation rather than refolding.

Gene Therapy Approaches

Viral vector-mediated overexpression of HSP70 or co-chaperones (DNAJB6, CHIP) has shown promising results in animal models, reducing protein aggregation and improving behavioral outcomes in Alzheimer’s, Parkinson’s, and Huntington’s Disease models^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}5.

Small Molecule HSF1 Activators

Compounds that directly activate HSF1 (e.g., HSF1A, celastrol) can boost the entire chaperone network rather than targeting individual HSPs. However, concerns about off-target effects and the oncogenic potential of sustained HSF1 activation have complicated clinical development^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}6.

Tauopathies and Chaperone Dysfunction

The 4R-Tauopathies

Four-repeat (4R) tauopathies — including Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), and Argyrophilic Grain Disease (AGD) — represent a group of neurodegenerative disorders characterized by the accumulation of hyperphosphorylated tau isoforms containing four microtubule-binding repeats. These disorders exhibit specific patterns of chaperone system failure that differ from amyloid-centric diseases like Alzheimer’s.

Chaperone Failure in Tauopathies

The HSP70/HSP90 chaperone system plays a critical role in tau quality control:

• HSP70 and tau disaggregation: The HSP70 disaggregation machinery (Hsc70-DNAJB1-HSP110) can actively depolymerize preformed tau fibrils by removing monomer units directly from fibril ends, demonstrating that tau aggregates are not irreversible endpoints^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}7

• HSP70 nucleation inhibition: HSP70 directly inhibits the nucleation and early elongation of tau fibrils by binding to tau monomers and oligomers with nanomolar affinity^{4" The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J Clin Invest*. 2007;117(3):648-658"2007 · DOI 10.1172/JCI29715Open reference}8

• HSP90 paradox: Unlike HSP70, Hsp90 preferentially stabilizes hyperphosphorylated tau species containing disease-associated phosphorylation sites (Ser202, Thr205, Ser396, Ser404), making Hsp90 inhibition a therapeutic strategy for promoting tau clearance

Small Heat Shock Proteins in Tauopathies

sHSPs show disease-specific accumulation patterns in tauopathies:

• HSPB5 (αB-crystallin): Found in PSP and CBD tau inclusions, particularly in glial cells. CSF HSPB5 levels serve as a potential biomarker

• HSPB1 (Hsp27): Binds to phosphorylated tau, preventing aggregation and protecting against membrane damage from tau aggregates

• HSPB8: Partners with BAG3 for selective autophagy-mediated tau clearance

Proteasome and CMA Dysfunction

• Proteasome impairment: PSP shows severely reduced proteasome chymotrypsin-like activity, correlating with tau pathology burden

• CMA dysfunction: LAMP-2A is reduced in PSP, impairing direct tau clearance. CBD shows LAMP-2A mislocalization

Therapeutic Implications

The chaperone system offers multiple tauopathy intervention points:

See Also

• Chaperone-Mediated Proteostasis in 4R-Tauopathies

See Also

• HSP70

• Chaperone-Mediated Proteostasis in 4R-Tauopathies

External Links

• NCBI Bookshelf — Heat Shock Proteins during Neurodegeneration

• PDB — HSP70 Structure

Background

The study of Molecular Chaperones In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Visual Pathway

flowchart TD
    A["Protein<br/>Misfolding -> BStress Signal<br/>HSF1 Activation"]

    B  -->  C["Heat Shock<br/>Factor 1 HSF1"]
    C  -->|"Trimerization"| D["HSF1<br/>Nuclear Translocation"]

    D  -->  E["HSP Gene<br/>Transcription"]
    E  -->  F["HSP70<br/>HSP90<br/>HSP40"]

    F  -->|"Client"| G["Misfolded<br/>Protein"]
    G  -->|"Binding"| H["Protein<br/>Refolding"]

    H  -->|"Success"| I["Native<br/>Conformation"]
    H  -->|"Failure"| J["Ubiquitination<br/>Proteasomal<br/>Degradation"]

    F  -->  K["Aggregate<br/>Disassembly"]
    K  -->  I

    L["HSP70/90<br/>Inhibitors"]  -->|"Therapeutic"| M["Enhanced<br/>Chaperone<br/>Activity"]
    M  -->  N["Reduced<br/>Protein<br/>Aggregation"]

    style A fill:#3e2200
    style I fill:#e8f5e8
    style N fill:#e8f5e8

Confidence Assessment

🟡 Moderate Confidence

Overall Confidence: 41%

Recent Research Updates (2024-2026)

Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.